Souhaitez-vous accéder aux communiqués récents ?

Landmark regulatory milestone makes the River stent available for adults with severe IIH – a debilitating, historically undertreated condition – who have failed medical therapy Serenity Medical...

NETANYA, Israel, March 31, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) today announced that it has entered into an option agreement to acquire control of DFSL, a developer of...

MGH collaboration to evaluate TRE-515 in ALS patients, advancing development of a first-in-class therapy targeting inflammation and nucleotide metabolism.

Potential breakthrough therapeutic targets $50B+ global immunotherapy market1 CHICAGO, March 31, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a...

ZymoChem has demonstrated that its bio-based and biodegradable SAP matches and surpasses the performance of conventional petroleum-based materials.

First clinical trial conducted in human subjects to evaluate CT2000 for the treatment of both acute ocular pain and chronic ocular surface pain commonly associated with dry eye disease CT2000 is a...

PolyPid Submits First Modules as Part of Rolling NDA Review; Completion expected in Second Quarter of 2026  U.S. Commercialization Partnership Negotiations on Track PETACH TIKVA, Israel, March 31,...

ROCKAWAY, N.J., March 31, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that Seth Abrams...

SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage development company focused on advancing novel therapeutics targeting degenerative retinal diseases...

WHITE PLAINS, N.Y., March 31, 2026 (GLOBE NEWSWIRE) -- Iantrek, Inc., a pioneer and leader in bio-interventional ophthalmic surgery (BIOS), today announced the introduction and US controlled release...